CAS 1058156-90-3
:Anlotinib
Description:
Anlotinib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of various cancers, including non-small cell lung cancer and soft tissue sarcoma. Its chemical structure allows it to inhibit multiple receptor tyrosine kinases, which play a crucial role in tumor growth and angiogenesis. Anlotinib is characterized by its ability to interfere with signaling pathways that promote cancer cell proliferation and survival. The substance is typically administered orally and has shown efficacy in clinical trials, leading to its approval in certain regions for specific cancer types. Its pharmacokinetics indicate a moderate half-life, allowing for once-daily dosing, and it is metabolized primarily in the liver. Common side effects may include hypertension, fatigue, and gastrointestinal disturbances. As with many targeted therapies, monitoring for adverse effects and drug interactions is essential during treatment. Overall, Anlotinib represents a significant advancement in targeted cancer therapy, providing a therapeutic option for patients with limited treatment alternatives.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 3 products.
Anlotinib
CAS:<p>Anlotinib is a drug that belongs to the class of small-molecule tyrosine kinase inhibitors and is currently being investigated for the treatment of various cancers. It inhibits signal transduction by binding to tyrosine kinases, which are enzymes that regulate a wide variety of cellular functions. The molecular docking analysis revealed that Anlotinib binds to the ATP binding site on multidrug resistance protein 1 (MRP1). This molecule also inhibits cell factor, matrix effect, and liver lesions in mice. Anlotinib has been shown to inhibit squamous carcinoma in humans with lung cancer, as well as eye disorders such as age-related macular degeneration. It also has potential as a biomarker for α1-acid glycoprotein levels in human serum.</p>Formula:C23H22FN3O3Purity:Min. 95%Molecular weight:407.45 g/mol
